Two-year follow-up of amyloid deposition in patients with Alzheimer's disease

Brain

Volumn 129, Issue 11, 2006, Pages 2856-2866

  Engler, Henry ^a   Forsberg, Anton ^c   Almkvist, Ove ^c,d   Blomquist, Gunnar ^a   Larsson, Emma ^c   Savitcheva, Irina ^b   Wall, Anders ^a   Ringheim, Anna ^a   Långström, Bengt ^a   Nordberg, Agneta ^c,e  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d STOCKHOLM UNIVERSITY   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Amyloid; FDG; Follow up; PET; PIB

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; MEMANTINE; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE C 11; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; BRAIN SCINTISCANNING; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; IN VIVO STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TEST RETEST RELIABILITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 33749506795     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl178     Document Type: Article

References (36)

1. Andersson JL, Thurfjell L. Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. J Comput Assist Tomogr 1997; 21: 136-44.
2. Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 2003; 100: 12462-7.
3. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2005; 2: 307-18.
4. Birks J. Does donepezil improve well-being for dementia due to Alzheimer's disease? Neuroepidemiology 2005; 24: 168-9.
5. Blomquist G, Ringheim A, Estrada S, Höglund U, Frändberg P, Nylén G, et al. Influx and net accumulation of PIB compared with CBF in a rhesus monkey. EANM05, Istanbul, Turkey. EJNM 2005; 32 (Suppl. 1): S263.
6. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239-59.
7. Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, et al. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci 2001; 21: 858-64.
8. Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergstrom M, et al. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging 2003; 30: 85-95.
9. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
10. Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 2005; 26: 104-11.
11. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-5.
12. Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 1993; 52: 594-600.
13. Inestrosa NC, Alvarez A, Dinamarca MC, Perez-Acle T, Colombres M. Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway. Curr Alzheimer Res 2005; 2: 301-6.
14. Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, et al. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005; 58: 748-57.
15. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001; 69: 1471-84.
16. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003; 23: 2086-92.
17. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
18. Lezak MD. Neuropsychological assessment. 4th edn. Oxford: Oxford University Press; 2004.
19. Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, Morgenstern JL, et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 2005; 280: 7677-84.
20. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-72.
21. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002; 12: 295-8.
22. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-54.
23. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995; 19: 541-7.
24. Mirra SS, Gearing M, McKeel DW Jr, Crain BJ, Hughes JP, van Belle G, et al. Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). J Neuropathol Exp Neurol 1994; 53: 303-15.
25. Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med 2002; 43: 983-90.
26. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
27. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25: 1528-47.
28. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. 'Preclinical' AD revisited: neuropathology of cognitively normal older adults. Neurology 2000; 55: 370-6.
29. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10: 24-35.
30. Stefanova E, Blennow K, Almkvist O, Hellstrom-Lindahl E, Nordberg A. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 2003; 338: 159-63.
31. Stefanova E, Wall Almkvist O, Nilsson A, Forsberg A, Långström B, Nordberg A. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm 2006; 113: 205-218.
32. Su JH, Cummings BJ, Cotman CW. Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res 1996; 739: 79-87.
33. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 2003; 11: 169-77.
34. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004; 12: 584-95.
35. Wang Y, Klunk WE, Huang GF, Debnath ML, Holt DP, Mathis CA. Synthesis and evaluation of 2-(37prime;-iodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. J Mol Neurosci 2002; 19: 11-6.
36. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol (Berl) 1989; 77: 314-9.